Translational research in neurology and neuroscience 2010: multiple sclerosis. Review uri icon

Overview

abstract

  • Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

publication date

  • July 12, 2010

Research

keywords

  • Antibodies, Monoclonal
  • Encephalomyelitis, Autoimmune, Experimental
  • Multiple Sclerosis
  • Peptides

Identity

PubMed Central ID

  • PMC3670826

Scopus Document Identifier

  • 77957949997

Digital Object Identifier (DOI)

  • 10.1001/archneurol.2010.158

PubMed ID

  • 20625066

Additional Document Info

volume

  • 67

issue

  • 11